---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008122"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:13:59.357234+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q4 2022 net loss $29.9M; cash $257.7M; ADI-001 ORR 75%

## Summary
- Q4 net loss $29.9M ($0.72 per share) vs $15.8M in Q4 2021; FY net loss $69.8M.
- Cash and equivalents $257.7M at Dec 31, 2022; expected runway into H1 2025.
- R&D expenses Q4 $25.0M, up 70% YoY; G&A $6.6M, flat.
- ADI-001 Phase 1 data: 75% ORR, 69% CR across doses; pivotal study plan in Q2 2023.
- IND for ADI-925 (CAd gamma delta T cell) expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-008122
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/0000950170-23-008122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/acet-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008122
- JSON: https://secwatch.observer/filing/0000950170-23-008122.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008122.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported for the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022 was $29.9 million, EPS a net loss of $0.72 per basic and diluted share.
  - Period: for the fourth quarter and year ended December 31, 2022
  - Net income: Net loss for the three months ended December 31, 2022 was $29.9 million
  - EPS: a net loss of $0.72 per basic and diluted share
  - Result: reported results
  source text: Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/0000950170-23-008122-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.